Showing information for HMDB0002005 ('methioninesulfoxide', 'methionine sulfoxide')

Metabolite information
HMDB ID HMDB0002005
Synonyms
2-amino-4-[Methylsulfinyl]-butanoate
2-amino-4-[Methylsulfinyl]-butanoic acid
Cucurbits
Cytoplasma
DL-Methionine sulfoxide
Digestion
Faecal
Faeces
Fecal
Flora
Gourds
Gramineae
L-Methionine R-oxide
L-Methionine [S]-S-oxide
L-Methionine sulfoxide
Legume
Met-so
Methionine sulfoxide, 35S-labeled, [+-]-isomer
Methionine sulfoxide, [+-]-isomer
Methionine sulfoxide, [2R]-isomer
Methionine sulfoxide, [2S]-isomer
Methionine sulfoxide, [R-[r*,s*]]-isomer
Methionine sulfoxide, [S-[r*,s*]]-isomer
Papilionoideae
S-Oxide-methionine
Stool
alpha-amino-gamma-[Methylsulfinyl]-butyric acid
Chemical formula C5H11NO3S
IUPAC name
2-amino-4-methanesulfinylbutanoic acid
CAS registry number 62697-73-8
Monisotopic molecular weight 165.045963913

Chemical taxonomy
Super class Organic acids and derivatives
Class Carboxylic acids and derivatives
Sub class Amino acids, peptides, and analogues

Biological properties
Pahtways
Cystathionine Beta-Synthase Deficiency
Glycine N-methyltransferase Deficiency
Homocystinuria-megaloblastic anemia due to defect in cobalamin metabolism, cblG complementation type
Hypermethioninemia
Methionine Adenosyltransferase Deficiency
Methionine Metabolism
Methylenetetrahydrofolate Reductase Deficiency [MTHFRD]
S-Adenosylhomocysteine [SAH] Hydrolase Deficiency
Author-emphasized biomarker in the paper(s)

Lung cancer metabolomics studies that identify HMDB0002005 ('methioninesulfoxide', 'methionine sulfoxide')

Reference Country Specimen Marker function Participants (Case) Participants (Control)
Cancer type Stage Number Gender (M,F) Age mean (range) (M/F) Smoking status Type Number Gender (M,F) Age mean (range) (M/F) Smoking status
Miyamoto et al. 2015 – blood diagnosis NSCLC, SCLC, mesothelioma, secondary metastasis to lung I, II, III, IV 11 4, 7 67 (61-73) / 67 (47-76) smoker, non-smoker healthy 11 5, 6 69 (61-83) / 54 (44-61) unknown
Fahrmann et al. 2015 – plasma diagnosis adenocarcinoma I, II, III, IV 52 17, 35 65.9 ± 9.66 – healthy 31 11, 20 64.1 ± 8.97 –
Fahrmann et al. 2015 – serum diagnosis adenocarcinoma I, II, III, IV 49 17, 32 65.9 ± 9.87 – healthy 31 11, 20 64.1 ± 8.97 –
Fahrmann et al. 2015 – serum diagnosis adenocarcinoma I, II, III, IV 43 21, 22 67.3 ± 10.10 – healthy 43 21, 22 65.9 ± 8.05 –
Miyamoto et al. 2015 – blood diagnosis adenocarcinoma unknown (mostly late stage) 18 10, 8 67 (50-85) / 62 (53-72) former, current healthy 20 8, 12 64 (49-80) / 66 (58-82) former, current
Moreno et al. 2018 – tissue therapy, diagnosis adenocarcinoma I, II, III 33 24, 9 62.11 ± 9.73 – tumor vs. adjacent normal tissue 33 24, 9 62.11 ± 9.73 –
Fahrmann et al. 2015 – plasma diagnosis adenocarcinoma I, II, III, IV 43 21, 22 67.3 ± 10.10 – healthy 43 21, 22 65.9 ± 8.05 –
Moreno et al. 2018 – tissue therapy, diagnosis squamous cell carcinoma I, II, III 35 35, 0 68.71 ± 7.46 – tumor vs. adjacent normal tissue 35 35, 0 68.71 ± 7.46 –
Wikoff et al. 2015b – tissue diagnosis adenocarcinoma I 39 15, 24 72.33 ± 8.78 smoker, non-smoker tumor vs. adjacent normal tissue 39 15, 24 72.33 ± 8.78 smoker, non-smoker
Reference Chromatography Ion source Positive/Negative mode Mass analyzer Identification level
Miyamoto et al. 2015 GC EI – TOF MS/MS
Fahrmann et al. 2015 GC EI – TOF –
Fahrmann et al. 2015 GC EI – TOF –
Fahrmann et al. 2015 GC EI – TOF –
Miyamoto et al. 2015 GC EI – TOF MS/MS
Moreno et al. 2018 LC, GC ESI, EI positive, negative LC: linear ion‐trap, GC: single‐quadrupole LC: MS/MS
Fahrmann et al. 2015 GC EI – TOF –
Moreno et al. 2018 LC, GC ESI, EI positive, negative LC: linear ion‐trap, GC: single‐quadrupole LC: MS/MS
Wikoff et al. 2015b GC EI – TOF –
Reference Data processing software Database search
Miyamoto et al. 2015 ChromaTOF software (Leco) UC Davis Metabolomics BinBase database
Fahrmann et al. 2015 – UC Davis Metabolomics BinBase database
Fahrmann et al. 2015 – UC Davis Metabolomics BinBase database
Fahrmann et al. 2015 – UC Davis Metabolomics BinBase database
Miyamoto et al. 2015 ChromaTOF software (Leco) UC Davis Metabolomics BinBase database
Moreno et al. 2018 – KEGG, HMDB
Fahrmann et al. 2015 – UC Davis Metabolomics BinBase database
Moreno et al. 2018 – KEGG, HMDB
Wikoff et al. 2015b BinBase NIST11, BinBase
Reference Difference method Mean concentration (case) Mean concentration (control) Fold change (case/control) P-value FDR VIP
Miyamoto et al. 2015 Analysis of Covariance 4847.45454545455 4774 1.01538637315763 0.989305286666861 – –
Fahrmann et al. 2015 regress (by the covariates: age, gender and smoking history [packs per year]), permutation test 758 ± 380 679 ± 285 1.12 0.454 0.773 –
Fahrmann et al. 2015 regress (by the covariates: age, gender and smoking history [packs per year]), permutation test 825 ± 483 917 ± 451 0.9 0.327 0.652 –
Fahrmann et al. 2015 regress (by the covariates: age, gender and smoking history [packs per year]), permutation test 353 ± 96 396 ± 128 0.892 0.119 0.367 –
Miyamoto et al. 2015 Analysis of Covariance 4094.66666666667 5455.55 0.750550662475216 0.0326676000313773 – –
Moreno et al. 2018 paired two‐sample t‐test, PLS-DA – – 1.20465438325205 0.031804077399662 0.0525421554828576 –
Fahrmann et al. 2015 regress (by the covariates: age, gender and smoking history [packs per year]), permutation test 156 ± 50 178 ± 47 0.88 0.013 0.093 –
Moreno et al. 2018 paired two‐sample t‐test, PLS-DA – – 1.23495945200495 0.00482484591575189 0.00706463677205506 –
Wikoff et al. 2015b OPLS-DA – – 1.8 – 0.045 –
Reference Classification method Cutoff value AUROC 95%CI Sensitivity (%) Specificity (%) Accuracy (%)
Miyamoto et al. 2015 – – – – – –
Fahrmann et al. 2015 random forest – – – – –
Fahrmann et al. 2015 random forest – – – – –
Fahrmann et al. 2015 random forest – – – – –
Miyamoto et al. 2015 – – – – – –
Moreno et al. 2018 – – – – – –
Fahrmann et al. 2015 random forest – – – – –
Moreno et al. 2018 – – – – – –
Wikoff et al. 2015b – – – – – –